CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Sumitomo Pharma Raises FY2026 Net Profit Forecast to JPY 94 Billion

By Public Technologies
  • Sumitomo Pharma raised its FY2026 net profit forecast to JPY 94 billion from JPY 77 billion on October 30, 2026.
  • Core operating profit guidance increased to JPY 105 billion from JPY 91 billion.
  • Revenue is now forecast at JPY 565 billion, versus JPY 540 billion, supported by stronger U.S. sales and European demand.
  • GEMTESA sales guidance rose to USD 752 million from USD 686 million, reflecting favorable first-half pricing.
  • A year-end dividend of JPY 15 per share is planned, reinstating payouts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk